New drug combo shows promise for Tough-to-Treat head and neck cancer
NCT ID NCT03082534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had returned or spread. The goal was to see if the combination could shrink tumors or slow the disease. Participants were grouped based on whether they had received similar treatments before, and the study measured how many responded and how long they lived without the cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Los Angeles Cancer Center
Los Angeles, California, 90095, United States
-
University of Michigan Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Washington School of Medicine Cancer Center
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can a scan tell who needs more surgery after head and neck cancer?